Cancer Drugs Reach All-Time High: The $100 Billion Disease that Depends on No Cure

portrait of a caucasian child suffering hair loss due to chemotherapy treatment to cure cancer

A child suffering hair loss due to chemotherapy treatment for cancer.

Health Impact News Editor Comments

The 2014 sales figures for cancer drugs were just published by the IMS Institute for Healthcare Informatics. Sales of cancer drugs have hit a new all-time record: $100 billion. That’s up more than 10 percent from 2013, and up from $75 billion five years earlier.

Cancer is obviously big business, as many new cancer drugs and now even cancer vaccines are in the pipe line.

Forty-five new drugs for cancer hit the market between 2010 and 2014, including 10 last year alone. These new drugs come with steep price tags, usually over $12,000.00 per month, or well over $100,000.00 per year.

Current forecasts for the cancer drug industry predict that the cancer drug industry will jump by 50% in the next 4 years, reaching $147 BILLION by 2018. This prediction, of course, assumes that none of these drugs will actually cure cancer, and the market will continue to grow.

An expose published by 60 Minutes last year (2014) revealed that new cancer drugs are seldom more effective than older cancer drugs, with the standard for “success” being able to extend the patient’s life by 42 days.

As we have previously reported, America has lost the war on cancer. Cancer is much too big of a business now to allow anyone to cure it. The U.S. economy, which is heavily dependent upon the pharmaceutical industry, would collapse if people started to believe and use alternative cancer therapies, many of which are natural and not able to be patented. Most people who fully understand this fact are heading south of the border to Mexico or over to Europe to find truly effective cancer cures that are not allowed by the FDA in the United States.

See:

The Cancer Industry is Too Prosperous to Allow a Cure

Unapproved but Effective Cancer Cures

Sources

International Business Times

NBC News

The Market Business

We Lost the War on Cancer – Review of Alternative Cancer Therapies

eBook
Retail : ~~$9⁹⁹~~
Now : $5⁹⁹

We have lost the war on cancer. At the beginning of the last century, one person in twenty would get cancer. In the 1940s it was one out of every sixteen people. In the 1970s it was one person out of ten. Today one person out of three gets cancer in the course of their life.

The cancer industry is probably the most prosperous business in the United States. In 2014, there will be an estimated 1,665,540 new cancer cases diagnosed and 585,720 cancer deaths in the US. $6 billion of tax-payer funds are cycled through various federal agencies for cancer research, such as the National Cancer Institute (NCI). The NCI states that the medical costs of cancer care are $125 billion, with a projected 39 percent increase to $173 billion by 2020.

The simple fact is that the cancer industry employs too many people and produces too much income to allow a cure to be found. All of the current research on cancer drugs is based on the premise that the cancer market will grow, not shrink.

John Thomas explains to us why the current cancer industry prospers while treating cancer, but cannot afford to cure it in Part I. In Part II, he surveys the various alternative cancer therapies that have been proven effective, but that are not approved by the FDA.